These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. PRMT5 as a druggable target for glioblastoma therapy. Banasavadi-Siddegowda YK; Welker AM; An M; Yang X; Zhou W; Shi G; Imitola J; Li C; Hsu S; Wang J; Phelps M; Zhang J; Beattie CE; Baiocchi R; Kaur B Neuro Oncol; 2018 May; 20(6):753-763. PubMed ID: 29106602 [TBL] [Abstract][Full Text] [Related]
3. Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma. Otani Y; Sur HP; Rachaiah G; Namagiri S; Chowdhury A; Lewis CT; Shimizu T; Gangaplara A; Wang X; Vézina A; Maric D; Jackson S; Yan Y; Zhengping Z; Ray-Chaudhury A; Kumar S; Ballester LY; Chittiboina P; Yoo JY; Heiss J; Kaur B; Banasavadi-Siddegowda YK Neuro Oncol; 2021 Sep; 23(9):1481-1493. PubMed ID: 33556161 [TBL] [Abstract][Full Text] [Related]
4. Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib. Banasavadi-Siddegowda YK; Namagiri S; Otani Y; Sur H; Rivas S; Bryant JP; Shellbourn A; Rock M; Chowdhury A; Lewis CT; Shimizu T; Walbridge S; Kumarasamy S; Shah AH; Lee TJ; Maric D; Yan Y; Yoo JY; Kumbar SG; Heiss JD; Kaur B Neurooncol Adv; 2022; 4(1):vdac095. PubMed ID: 35875691 [TBL] [Abstract][Full Text] [Related]
5. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma. Holmes B; Benavides-Serrato A; Saunders JT; Landon KA; Schreck AJ; Nishimura RN; Gera J J Neurooncol; 2019 Oct; 145(1):11-22. PubMed ID: 31473880 [TBL] [Abstract][Full Text] [Related]
6. Engagement of cellular prion protein with the co-chaperone Hsp70/90 organizing protein regulates the proliferation of glioblastoma stem-like cells. Iglesia RP; Prado MB; Cruz L; Martins VR; Santos TG; Lopes MH Stem Cell Res Ther; 2017 Apr; 8(1):76. PubMed ID: 28412969 [TBL] [Abstract][Full Text] [Related]
7. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Yan F; Alinari L; Lustberg ME; Martin LK; Cordero-Nieves HM; Banasavadi-Siddegowda Y; Virk S; Barnholtz-Sloan J; Bell EH; Wojton J; Jacob NK; Chakravarti A; Nowicki MO; Wu X; Lapalombella R; Datta J; Yu B; Gordon K; Haseley A; Patton JT; Smith PL; Ryu J; Zhang X; Mo X; Marcucci G; Nuovo G; Kwon CH; Byrd JC; Chiocca EA; Li C; Sif S; Jacob S; Lawler S; Kaur B; Baiocchi RA Cancer Res; 2014 Mar; 74(6):1752-65. PubMed ID: 24453002 [TBL] [Abstract][Full Text] [Related]
8. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Sachamitr P; Ho JC; Ciamponi FE; Ba-Alawi W; Coutinho FJ; Guilhamon P; Kushida MM; Cavalli FMG; Lee L; Rastegar N; Vu V; Sánchez-Osuna M; Coulombe-Huntington J; Kanshin E; Whetstone H; Durand M; Thibault P; Hart K; Mangos M; Veyhl J; Chen W; Tran N; Duong BC; Aman AM; Che X; Lan X; Whitley O; Zaslaver O; Barsyte-Lovejoy D; Richards LM; Restall I; Caudy A; Röst HL; Bonday ZQ; Bernstein M; Das S; Cusimano MD; Spears J; Bader GD; Pugh TJ; Tyers M; Lupien M; Haibe-Kains B; Artee Luchman H; Weiss S; Massirer KB; Prinos P; Arrowsmith CH; Dirks PB Nat Commun; 2021 Feb; 12(1):979. PubMed ID: 33579912 [TBL] [Abstract][Full Text] [Related]
9. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Zheng H; Ying H; Yan H; Kimmelman AC; Hiller DJ; Chen AJ; Perry SR; Tonon G; Chu GC; Ding Z; Stommel JM; Dunn KL; Wiedemeyer R; You MJ; Brennan C; Wang YA; Ligon KL; Wong WH; Chin L; DePinho RA Nature; 2008 Oct; 455(7216):1129-33. PubMed ID: 18948956 [TBL] [Abstract][Full Text] [Related]
10. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature. Jones KA; Gilder AS; Lam MS; Du N; Banki MA; Merati A; Pizzo DP; VandenBerg SR; Gonias SL Neuro Oncol; 2016 May; 18(5):667-78. PubMed ID: 26420897 [TBL] [Abstract][Full Text] [Related]
11. Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth. Zhang S; Ma Y; Hu X; Zheng Y; Chen X J Cell Mol Med; 2019 Feb; 23(2):1333-1342. PubMed ID: 30461193 [TBL] [Abstract][Full Text] [Related]
13. Targeting osteopontin suppresses glioblastoma stem-like cell character and tumorigenicity in vivo. Lamour V; Henry A; Kroonen J; Nokin MJ; von Marschall Z; Fisher LW; Chau TL; Chariot A; Sanson M; Delattre JY; Turtoi A; Peulen O; Rogister B; Castronovo V; Bellahcène A Int J Cancer; 2015 Sep; 137(5):1047-57. PubMed ID: 25620078 [TBL] [Abstract][Full Text] [Related]
14. Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Zheng H; Ying H; Yan H; Kimmelman AC; Hiller DJ; Chen AJ; Perry SR; Tonon G; Chu GC; Ding Z; Stommel JM; Dunn KL; Wiedemeyer R; You MJ; Brennan C; Wang YA; Ligon KL; Wong WH; Chin L; dePinho RA Cold Spring Harb Symp Quant Biol; 2008; 73():427-37. PubMed ID: 19150964 [TBL] [Abstract][Full Text] [Related]
16. PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line. Moon SH; Kim DK; Cha Y; Jeon I; Song J; Park KS Int J Oncol; 2013 Mar; 42(3):921-8. PubMed ID: 23314408 [TBL] [Abstract][Full Text] [Related]